In international multicentre comparative clinical trials carried out by dermatologists in 717 patients with non-infected acute eczematous
dermatoses at 28 trial centres in Austria, Germany, Holland, Switzerland and Yugoslavia,
halometasone cream exhibited a very satisfactory
therapeutic effect in acute
contact dermatitis,
atopic dermatitis, nummular
dermatitis and seborrhoeic
dermatitis. It yielded 'good' to 'very good' results in 89.7% of the 333 patients treated with
halometasone cream.
Halometasone cream was significantly more effective than Diproderm,
Diprosone and
Ultralan creams with respect to the overall success rate, the percentage of patients with 'very good' results and early cures. It proved marginally superior to
Halciderm cream in therapeutic efficacy. The onset of
therapeutic effect was more rapid in patients treated with
halometasone cream than in those on treatment with comparative preparations.
Halometasone cream was well tolerated and neither skin
atrophy nor any systemic effect due to the transcutaneous systemic absorption of the
corticoid was observed. In view of the rapid onset of action, very good efficacy and tolerability,
halometasone cream, with agreeable cosmetic and applicatory properties, may be considered as a suitable
corticosteroid topical for the treatment of acute eczematous and other
corticosteroid-responsive
dermatoses.